Free shipping on all orders over $ 500

CUDC-305

Cat. No. M1725
CUDC-305 Structure
Size Price Availability Quantity
10mg USD 220 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

CUDC-305 is a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.CUDC-305 shows high affinity for HSP90α/β (IC50, ~100 nmol/L) and HSP90 complex derived from cancer cells (IC50, 48.8 nmol/L). It displays potent antiproliferative activity against a broad range of cancer cell lines (mean IC50, 220 nmol/L). CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life,20.4 hours) compared with normal tissues. Furthermore, CUDC-305 can cross bloodbrain barrier and reach therapeutic levels in brain tissue. CUDC-305 exhibits dosedependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model. CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non–small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia. Correlating with its efficacy in these various tumor models, CUDC-305 robustly inhibits multiple signaling pathways, including PI3K/AKT and RAF/MEK/ERK, and induces apoptosis. In combination studies, CUDC-305 enhances the antitumor activity of standard-of-care agents in breast and colorectal tumor models.

Protocol
Cell Experiment
Cell lines BT474, N87, H1975, H1993, Calu-6 and H460 cells line
Preparation method Cell growth and viability assay. Human cancer cell lines were purchased from American Type Culture Collection and plated at 5,000 to 10,000 per well in 96-well plates with culture medium, as suggested by the provider. The cells were then incubated with compounds at various concentrations for 120 h. Growth inhibition was assessed by ATP content assay using the Perkin-Elmer ATPlite kit. Briefly, a 25-μL cell lysis solution was added to the 50-μL phenol red–free culture medium per well to lyse cells and stabilize ATP. Then 25-μL substrate solutions were added to the wells, and subsequently, luminescence was measured with a TopCount liquid scintillation analyzer (Perkin-Elmer). Values were expressed as a percentage relative to those obtained in untreated controls. IC50 values were calculated using PRISM software (GraphPad Software) with sigmoidal dose-response curve fitting.
Concentrations 0~900nM
Incubation time 120h
Animal Experiment
Animal models U87MG glioblastoma tumor models
Formulation formulated in 30% Captisol
Dosages single 160 mg/kg
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 442.58
Formula C22H30N6O2S
CAS Number 1061318-81-7
Purity >99%
Solubility DMSO
Storage at -20°C
Customer Product Validations & Biological Datas
Source Scientific Reports (2017). Figure 1.CUDC305 (AbMole BioScience Houston, TX, USA)
Method MTS based assay
Cell Lines 5637 bladder carcinoma cells
Concentrations 0, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, and 100 μM
Incubation Time 24, 48, or 72 h.
Results These results indicate that these HSP90 inhibitors potently inhibit cell proliferation and induce cell toxicity in bladder cancer 5637 cells.
Rating
Product Citations
References

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao et al. Mol Cancer Ther. 2009 Dec;8(12):3296-306. PMID: 19952121.

CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao et al. Clin Cancer Res. 2009 Jun 15;15(12):4046-57. PMID: 19509149.

Related HSP90 Products
Teprenone

Teprenone(Geranylgeranylacetone; GGA)is commonly utilized to protect the gastric mucosa in peptic ulcer disease; has been shown to protect the myocardium from ischemia/reperfusion by activating heat shock proteins.

Celastrol

Celastrol is a potent antioxidant and anti-inflammatory agent and a novel HSP90 inhibitor.

CH5138303

CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.

Retaspimycin

Retaspimycin is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90).

KW-2478

KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: CUDC-305 supplier, HSP90, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.